Macrogenics Inc MGNX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX
-
Shareholders of MacroGenics, Inc. Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX
-
MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm
-
Hagens Berman Alerts MacroGenics (MGNX) Investors to Today’s Lead Plaintiff Deadline in Securities Class Action
-
MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX
-
MGNX DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action – MGNX
-
MacroGenics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2024 Deadline to file Lead Plaintiff Motion
-
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Trading Information
- Previous Close Price
- $3.04
- Day Range
- $2.98–3.09
- 52-Week Range
- $2.95–21.88
- Bid/Ask
- $3.00 / $3.05
- Market Cap
- $190.68 Mil
- Volume/Avg
- 438,479 / 910,607
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.80
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 339
- Website
- https://www.macrogenics.com
Comparables
Valuation
|
Metric
|
MGNX
|
CGON
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.30 | 4.44 | 2.68 |
Price/Sales | 4.80 | 245.06 | 221.87 |
Price/Cash Flow | — | — | — |
Price/Earnings
MGNX
CGON
CLDX
Financial Strength
|
Metric
|
MGNX
|
CGON
|
CLDX
|
|---|---|---|---|
Quick Ratio | 2.53 | 46.66 | 29.06 |
Current Ratio | 2.71 | 47.57 | 29.36 |
Interest Coverage | −128.87 | — | — |
Quick Ratio
MGNX
CGON
CLDX
Profitability
|
Metric
|
MGNX
|
CGON
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −59.21% | −15.24% | −19.66% |
Return on Equity (Normalized) | −120.96% | −26.61% | −20.83% |
Return on Invested Capital (Normalized) | −102.88% | −25.60% | −20.72% |
Return on Assets
MGNX
CGON
CLDX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xftsqmhwv | Kycly | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zjjjgzpsf | Tzcvwg | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nzwbvknnz | Cljfd | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gytznfvxf | Gwkcr | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Xcmygglg | Zxhh | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Pdrrwmrsh | Kvz | $28.0 Bil | |||
| Moderna Inc
MRNA
| Fvbldsjf | Zsdg | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Qdkyhsyx | Kqgsl | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lbwhnrkh | Lhyrgyc | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vkkhycmkk | Glctxk | $12.6 Bil |
United States